Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Prostate Cancer and Prostatic Diseases|March 26, 2014
Novel bone-targeting agents in prostate cancerC Albany, N M Hahn
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Long-term toxicity of cisplatin in germ-cell tumor survivorsM Chovanec, M Abu Zaid, N Hanna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014N Adra, S K Althouse, H Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206N Adra, L H Einhorn, S K Althouse, et al.
Urologic Oncology|June 9, 2018
Commentary on "Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy."D E Thomas, H Z Kaimakliotis, K R Rice, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2009
A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67N M Hahn, R T Zon, M Yu, et al.
ESMO Open|March 21, 2021
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamideD P Petrylak, U N Vaishampayan, K R Patel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2017
Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumorsC Albany, N Adra, A C Snavely, et al.
Pageof 1